A Study of IBI362 in Participants With Obesity or Overweight
NCT ID: NCT05607680
Last Updated: 2024-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
610 participants
INTERVENTIONAL
2022-11-14
2024-04-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of IBI362 9 mg in Chinese Adults With Obesity
NCT06164873
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
NCT04904913
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
NCT07255209
A Study of IBI3032 in Chinese Participants With Overweight or Obesity
NCT07170319
Clinical Study of IBI362 in Healthy Chinese Male Subjects
NCT04773977
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo,SC,once a week for 48 weeks
Placebo
Placebo administered subcutaneously (SC) once a week.
IBI362 4 mg
2 mg,SC,once a week for 4 weeks 4 mg,SC,once a week for 44 weeks
IBI362
IBI362 administered subcutaneously (SC) once a week.
IBI362 6 mg
2 mg,SC,once a week for 4 weeks 4 mg,SC,once a week for 4 weeks 6 mg,SC,once a week for 40 weeks
IBI362
IBI362 administered subcutaneously (SC) once a week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Placebo administered subcutaneously (SC) once a week.
IBI362
IBI362 administered subcutaneously (SC) once a week.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Weight change \> 5.0% after diet and exercise control for at least 12 weeks before screening;
* Have used or are currently using weight loss drugs within 3 months before screening;
* History of pancreatitis;
* Family or personal history of thyroid C-cell carcinoma or multiple endocrine neoplasia (MEN) 2A or 2B；
* History of moderate to severe depression or severe mental illness;
* Any lifetime history of a suicide attempt
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Innovent Biologics (Suzhou) Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xuancheng People's Hospital
Xuancheng, Anhui, China
People's Hospital of Peking University
Beijing, Beijing Municipality, China
Luoyang Third People's Hospital
Luoyang, He'nan, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, He'nan, China
The First Affiliated Hospital of Nanyang Medical University
Nanyang, He'nan, China
The Third Affiliated Hospital of Xinxiang Medical University
Xinxiang, He'nan, China
Hebei Petro China Central Hospital
Langfang, Hebei, China
The First People's Hospital Of Kunshan
Kunshan, Jiangsu, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Affiliated Hospital Of Nantong University
Nantong, Jiangsu, China
Suzhou Municipal Hospital
Suzhou, Jiangsu, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
China-Japan Union Hospital of Jilin University
Changchun, Jilin, China
Shenyang Fifth People's Hospital
Shenyang, Liaoning, China
Jinan Central Hospital
Ji'nan, Shandong, China
Shandong Provincial Third Hospital
Ji'nan, Shandong, China
Qilu Hospital Of Shandong University (Qingdao)
Qingdao, Shandong, China
Tai'an Central Hospital
Tai’an, Shandong, China
Zibo Municipal Hospital
Zibo, Shandong, China
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
Yan'an University Xianyang Hospital
Xianyang, Shanxi, China
Huzhou Central Hospital
Huzhou, Zhejiang, China
Lishui Central Hospital
Lishui, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, Zhao Y, Qiu W, Huang C, Chen L, Zhong S, Han J, Zhang Y, Lian Q, Yang P, Lv L, Gu J, Liu Z, Deng H, Wang Y, Li L, Pei L, Qian L; GLORY-1 Investigators. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025 Jun 12;392(22):2215-2225. doi: 10.1056/NEJMoa2411528. Epub 2025 May 25.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIBI362B301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.